BCAS1 Antibody
| Code | Size | Price |
|---|
| PSI-5625-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5625-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
BCAS1 Antibody: AIBC1, NABC1, AIBC1, Breast carcinoma-amplified sequence 1, Amplified and overexpressed in breast cancer
Application Note:
BCAS1 antibody can be used for detection of BCAS1 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
BCAS1 Antibody: BCAS1 was identified through positional cloning and was found to be overexpressed in most but not all breast cancer cells lines. Little is known about this protein; BCAS1 is cytoplasmically localized and is thought to form homodimers through coiled-coil structures. High levels of BCAS1 mRNA are seen in brain and prostate tissues, with lower amounts observed in colon, intestine and testis. Cells engineered to overexpress BCAS1 did not lose anchorage-dependent growth or increase their rate of growth, suggesting that BCAS1 is not a prototypical oncogene. The BCAS1 gene was also found to be amplified in other carcinomas such as pancreatic carcinoma, suggesting that BCAS1 may play in important role in the control of cell proliferation.
Background References:
- Collins C, Rommens JM, Kowbel D, et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc. Natl. Acad. Sci. USA1998; 95:8703-8.
- Beardsley DI, Kowbel D, Lataxes TA, et al. Characterization of the novel amplified in breast cancer-1 (NABC1) gene product. Exp. Cell Res.2003; 290:402-13.
- Loukopoulos P, Shibata T, Katoh H, et al. Genome-wide assay-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci.2007; 98:392-400.
Buffer:
BCAS1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Rat: (75%)
Immunogen:
BCAS1 antibody was raised against a 16 amino acid synthetic peptide near the carboxy terminus of human BCAS1.
The immunogen is located within amino acids 460 - 510 of BCAS1.
The immunogen is located within amino acids 460 - 510 of BCAS1.
NCBI Gene ID #:
8537
NCBI Official Name:
breast carcinoma amplified sequence 1
NCBI Official Symbol:
BCAS1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
EAW75575
Protein GI Number:
119595981
Purification:
BCAS1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
Swissprot #:
O75363
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | BCAS1 Peptide | PSI-5625P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|